A single asterisk (*) indicates differences observed between groups that were ≥2.5% for events with an incidence ≥2.5% in both groups or ≥2-fold for events with an incidence <2.5% in one or both groups (calculations were made using the number of patients [no rounding]; in the event of a null value for one treatment, only situations where ≥2 cases were observed in the other treatment group are indicated); the symbol is placed to the right of the value observed for the drug in disfavor. A double asterisk (**) indicates differences
observed between treatment groups according to the same rule and where the number of patients experiencing an event was ≥10 in either group; the symbols are placed to the right of the www.selleckchem.com/products/GDC-0449.html value observed for the drug in disfavor Table VI shows the incidences of SADRs in the combined double-blind and open-label studies, stratified by administration route. These were low considering the number of patients treated (oral: moxifloxacin 0.6% versus
comparator 0.5%; intravenous/oral: moxifloxacin 2.8% BMN 673 mouse versus comparator 1.9%; intravenous: moxifloxacin 1.0% versus comparator 0.8%). In the oral population, the incidences of SADRs within each SOC were similar between the treatment groups, with no individual SADR occurring at an incidence >0.15% https://www.selleckchem.com/products/lee011.html in either the moxifloxacin or the comparator groups. In the intravenous/oral population, the SOCs associated with the highest incidence of events in both treatment
groups were ‘infections and infestations’ (moxifloxacin 24 [0.7%] versus comparator 23 [0.7%]), [investigations’ (moxifloxacin 23 [0.7%] versus comparator 7 [0.2%]), and ‘gastrointestinal disorders’ (moxifloxacin 15 [0.4%] versus comparator 7 [0.2%]). Differences in disfavor of moxifloxacin versus comparator, using a 2-fold cut-off and events dipyridamole affecting at least 10 patients, were seen only for the SOCs ‘gastrointestinal disorders’ and [investigations’. Of note, ‘cardiac disorders’ were less frequent for moxifloxacin than for comparators (moxifloxacin 5 [0.1%] versus comparator 11 [0.3%] patients). In the intravenous-only population, the numbers were all very small, limiting the meaning and accuracy of any comparison. In the moxifloxacin and comparator intravenous groups, only one and two patients, respectively, experienced a cardiac disorder. Table VI Serious adverse drug reactions presented by system organ class in patients valid for the safety analysis, treated with moxifloxacin or a comparator and stratified by route of administration (oral only; intravenous followed by oral [sequential]; intravenous only). A single asterisk (*) indicates differences observed between groups that were ≥2.5% for events with an incidence ≥2.5% in both groups or ≥2-fold for events with an incidence <2.